|
1
|
Han G, Foster BA, Mistry S, Buchanan G,
Harris JM, Tilley WD and Greenberg NM: Hormone status selects for
spontaneous somatic androgen receptor variants that demonstrate
specific ligand and cofactor dependent activities in autochthonous
prostate cancer. J Biol Chem. 276:11204–11213. 2001. View Article : Google Scholar
|
|
2
|
Steinkamp MP, O'Mahony OA, Brogley M,
Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R,
Chinnaiyan A, Rubin MA, et al: Treatment-dependent androgen
receptor mutations in prostate cancer exploit multiple mechanisms
to evade therapy. Cancer Res. 69:4434–4442. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li P, Yang R and Gao W-Q: Contributions of
epithelial-mesenchymal transition and cancer stem cells to the
development of castration resistance of prostate cancer. Mol
Cancer. 13:552014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Friedlander TW, Roy R, Tomlins SA, Ngo VT,
Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann
MM, et al: Common structural and epigenetic changes in the genome
of castration-resistant prostate cancer. Cancer Res. 72:616–625.
2012. View Article : Google Scholar
|
|
5
|
Berrevoets CA, Veldscholte J and Mulder E:
Effects of antiandrogens on transformation and transcription
activation of wild-type and mutated (LNCaP) androgen receptors. J
Steroid Biochem Mol Biol. 46:731–736. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McDonald S, Brive L, Agus DB, Scher HI and
Ely KR: Ligand responsiveness in human prostate cancer: Structural
analysis of mutant androgen receptors from LNCaP and CWR22 tumors.
Cancer Res. 60:2317–2322. 2000.PubMed/NCBI
|
|
7
|
Felgueiras J, Silva JV and Fardilha M:
Prostate cancer: The need for biomarkers and new therapeutic
targets. J Zhejiang Univ Sci B. 15:16–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schrecengost R and Knudsen KE: Molecular
pathogenesis and progression of prostate cancer. Semin Oncol.
40:244–258. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nelson WG, Yegnasubramanian S, Agoston AT,
Bastian PJ, Lee BH, Nakayama M and De Marzo AM: Abnormal DNA
methylation, epigenetics, and prostate cancer. Front Biosci.
12:4254–4266. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yegnasubramanian S, Haffner MC, Zhang Y,
Gurel B, Cornish TC, Wu Z, Irizarry RA, Morgan J, Hicks J, DeWeese
TL, et al: DNA hypomethylation arises later in prostate cancer
progression than CpG island hypermethylation and contributes to
metastatic tumor heterogeneity. Cancer Res. 68:8954–8967. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Scher HI and Sawyers CL: Biology of
progressive, castrationresistant prostate cancer: Directed
therapies targeting the androgen-receptor signaling axis. J Clin
Oncol. 23:8253–8261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tian J, Lee SO, Liang L, Luo J, Huang CK,
Li L, Niu Y and Chang C: Targeting the unique methylation pattern
of androgen receptor (AR) promoter in prostate stem/progenitor
cells with 5-aza-2′-deoxycytidine (5-AZA) leads to suppressed
prostate tumorigenesis. J Biol Chem. 287:39954–39966. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McCabe MT, Low JA, Daignault S, Imperiale
MJ, Wojno KJ and Day ML: Inhibition of DNA methyltransferase
activity prevents tumorigenesis in a mouse model of prostate
cancer. Cancer Res. 66:385–392. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zorn CS, Wojno KJ, McCabe MT, Kuefer R,
Gschwend JE and Day ML: 5-aza-2′-deoxycytidine delays
androgen-independent disease and improves survival in the
transgenic adenocarcinoma of the mouse prostate mouse model of
prostate cancer. Clin Cancer Res. 13:2136–2143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gravina GL, Marampon F, Di Staso M,
Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V and
Festuccia C: 5-Azacitidine restores and amplifies the bicalutamide
response on preclinical models of androgen receptor expressing or
deficient prostate tumors. Prostate. 70:1166–1178. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gao L and Alumkal J: Epigenetic regulation
of androgen receptor signaling in prostate cancer. Epigenetics.
5:100–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fialova B, Smesny Trtkova K, Paskova L,
Langova K and Kolar Z: Effect of histone deacetylase and DNA
methyltransferase inhibitors on the expression of the androgen
receptor gene in androgen-independent prostate cancer cell lines.
Oncol Rep. 29:2039–2045. 2013.PubMed/NCBI
|
|
18
|
Trtkova K, Paskova L, Matijescukova N,
Strnad M and Kolar Z: Binding of AR to SMRT/N-CoR complex and its
co-operation with PSA promoter in prostate cancer cells treated
with natural histone deacetylase inhibitor NaB. Neoplasma.
57:406–414. 2010. View Article : Google Scholar
|
|
19
|
Walton TJ, Li G, Seth R, McArdle SE,
Bishop MC and Rees RC: DNA demethylation and histone deacetylation
inhibition co-operate to re-express estrogen receptor beta and
induce apoptosis in prostate cancer cell-lines. Prostate.
68:210–222. 2008. View Article : Google Scholar
|
|
20
|
Jarrard DF, Kinoshita H, Shi Y, Sandefur
C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB and Nassif N:
Methylation of the androgen receptor promoter CpG island is
associated with loss of androgen receptor expression in prostate
cancer cells. Cancer Res. 58:5310–5314. 1998.PubMed/NCBI
|
|
21
|
Paskova L, Smesny Trtkova K, Fialova B,
Benedikova A, Langova K and Kolar Z: Different effect of sodium
butyrate on cancer and normal prostate cells. Toxicol In Vitro.
27:1489–1495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim J, Park H, Im JY, Choi WS and Kim HS:
Sodium butyrate regulates androgen receptor expression and cell
cycle arrest in human prostate cancer cells. Anticancer Res.
27A:3285–3292. 2007.
|
|
23
|
Pajak B, Orzechowski A and Gajkowska B:
Molecular basis of sodium butyrate-dependent proapoptotic activity
in cancer cells. Adv Med Sci. 52:83–88. 2007.
|
|
24
|
Qiu J, Gao Z and Shima H: Growth of human
prostate cancer cells is significantly suppressed in vitro with
sodium butyrate through apoptosis. Oncol Rep. 27:160–167. 2012.
|
|
25
|
Mu D, Gao Z, Guo H, Zhou G and Sun B:
Sodium butyrate induces growth inhibition and apoptosis in human
prostate cancer DU145 cells by up-regulation of the expression of
Annexin A1. PLoS One. 8:e749222013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Patra A, Deb M, Dahiya R and Patra SK:
5-Aza-2′-deoxycytidine stress response and apoptosis in prostate
cancer. Clin Epigenetics. 2:339–348. 2011. View Article : Google Scholar
|
|
27
|
Zhang J and Zhong Q: Histone deacetylase
inhibitors and cell death. Cell Mol Life Sci. 71:3885–3901. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J,
Chen Z, Beroukhim R, Wang H, Lupien M, et al: Androgen receptor
regulates a distinct transcription program in androgen-independent
prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heemers HV and Tindall DJ: Androgen
receptor (AR) coregulators: A diversity of functions converging on
and regulating the AR transcriptional complex. Endocr Rev.
28:778–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
